Research programme: deuterium stabilised enantiomers - DeuteRx

Alternative Names: Deuterated bupropion; Deuterated CC11006; Deuterated inolitazone; Deuterated mitoglitazone; Deuterated MSDC 0160; Deuterium stabilised enantiomer bupropion; Deuterium stabilised enantiomer CC 11006; Deuterium stabilised enantiomer inolitazone; Deuterium stabilised enantiomer mitoglitazone; Deuterium stabilised enantiomer MSDC 0160; DRX 184; DRX 195; DRX-065; DRX-164; DRX-194

Latest Information Update: 23 Aug 2016

Price : ^*

* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

Originator DeuteRx
Developer Celgene Corporation; DeuteRx
Class Indans; Piperidines; Small molecules; Thiazolidinediones
Mechanism of Action Acetylcholinesterase inhibitors; Adrenergic receptor antagonists; Dopamine uptake inhibitors; Immunomodulators; Interleukin 1 beta inhibitors; Interleukin 10 stimulants; Mitochondrial protein stimulants; Peroxisome proliferator-activated receptor gamma agonists; Platelet ADP receptor antagonists; Tumour necrosis factor inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

Highest Development Phases

Research Acute coronary syndromes; Alzheimer's disease; CNS disorders; Colorectal cancer; Inflammation; Major depressive disorder; Multiple myeloma; Myelodysplastic syndromes; Sickle cell anaemia; Type 2 diabetes mellitus

Most Recent Events

22 Aug 2016 DeuteRx plans a phase Ia trial in Healthy volunteers in USA
10 Apr 2015 Early research in Alzheimer's disease in USA (PO) (91757340
01 Apr 2015 Early research in Inflammation in USA (PO)

Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

Login with a username/password associated to an account with a valid subscription
Contact your organization’s admin about adding this content to your AdisInsight subscription
Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.